Concert Pharmaceuticals — Technical Presentation (September 2019)
20 slides from Concert Pharmaceuticals's technical presentation, Sep 5, 2019
Slide 1: CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata
CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata September 3, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contai
Slide 3: Alopecia Areata: A Serious Medical Disease
Alopecia Areata: A Serious Medical Disease • A devastating and poorly treated autoimmune disease • Up to 650,000 patients affected with alopecia areata in the U.S. at any given time* • Chronic condition affecting women, men and children of all ages • Disease profoundly impacts patients; associated w
Slide 4: CTP-543 Phase 2 Dose-Ranging Trial Design
CTP-543: Phase 2 Dose-Ranging Trial • Double-blind, randomized, placebo-controlled trial in Trial Design adult patients with moderate-to-severe alopecia areata • Entry criteria of at least 50% hair loss as measured by Severity of Alopecia Tool (SALT) • Patients sequentially randomized to receive one
Slide 5: Demographics
Demographics CTP-543 CTP-543 CTP-543 Placebo 4 mg 8 mg 12 mg Randomized Population 44 30 38 37 Efficacy Population 43 28 38 36 Age: Mean (SD) 38 (14%) 36 (11%) 37(14%) 36 (12%) Males, n (%) 15 (34%) 8 (27%) 12 (32%) 9 (24%) Females, n (%) 29 (66%) 22 (73%) 26 (68%) 28 (76%) Race: n (%) White 33 (75%
Slide 6: Baseline Alopecia Areata Characteristics
Baseline Alopecia Areata Characteristics CTP-543 CTP-543 CTP-543 Placebo 4 mg 8 mg 12 mg Episode Duration: Yr, Mean 4.1 6 3.8 3.5 SALT score, Mean (SD) 86.8 (18.4) 88.8 (16.2) 89.1 (16.4) 87.3 (18.7) AA Patchy, n (%) 21 (47.7%) 16 (53.3%) 16 (42.1%) 16 (43.2%) AA Totalis, n (%) 6 (13.6%) 2 (6.7%) 6
Slide 7: Primary Analysis: Responders at Week 24
Primary Analysis: Responders at Week 24 Patients with ≥ 50% Change in SALT Relative to Baseline 60 58% 50 • 12 mg BID 47% responders 40 average 86% SALT improvement 30 • 8 mg BID responders average 20 21% % Patients per Treatment Treatment per % Patients 78% SALT improvement 10 9 % 0 Placebo 4 mg BI
Slide 8: Responders: ≥50% Change in SALT Relative to Baseline
Responders: ≥ 50% Change in SALT Relative to Baseline 60 *** 58% *** 50 *** 47% *** 40 30 21% 20 % Patients per Treatment Treatment per % Patients 10 9 % 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Placebo 4 mg BID 8 mg BID 12 mg BID *** P < 0.001 vs PBO * P < 0.05 vs PBO 8
Slide 9: Responders: ≥75% Change in SALT Relative to Baseline
Responders: ≥ 75% Change in SALT Relative to Baseline 60 50 *** 42% 40 *** 30 29% % Patients per Treatment Treatment Patientsper % 20 14% 10 7 % 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Placebo 4 mg BID 8 mg BID 12 mg BID *** P < 0.001 vs PBO * P < 0.05 vs PBO 9
Slide 10: Responders: ≥90% Change in SALT Relative to Baseline
Responders: ≥ 90% Change in SALT Relative to Baseline 60 50 40 *** ***+ 36% 30 20 % Patients per Treatment Treatment per % Patients 16% 10 2 % 0 0% Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 *** P < 0.001 vs PBO Placebo 4 mg BID 8 mg BID 12 mg BID * P < 0.05 vs PBO + P < 0.05 vs 8 mg 10
Slide 11: Patient SALT Improvement Thresholds
Patient SALT Improvement Thresholds 70 Relative Change in SALT from Baseline to Week 24 60 *** 58% 50 *** 47% *** 40 + 42% *** 36% 30 29% 20 % of Patients per Treatment per Patients % of 21% 16% 10 14% 9% 7% 2% 0 ≥ 50% ≥ 75% ≥ 90% *** P < 0.001 vs PBO Placebo 4 mg BID 8 mg BID 12 mg BID * P < 0.05 v
Slide 12: Relative Change in SALT All Treated Patients Per Cohort
Relative Change in SALT All Treated Patients Per Cohort 60 *** 50 *** 50% *** *** 42% 40 * * 30 + * 20 17% 10 9% 0 Mean % Relative Change from Baseline from Change Relative % Mean -10 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 *** P < 0.001 vs PBO Placebo 4 mg BID 8 mg BID 12 mg BID * P < 0.05 vs
Slide 13: Patient Global Impression of Improvement: Responders
Patient Global Impression of Improvement: Responders Patient Rated as “Much Improved” or “Very Much Improved” at Week 24 100 90 80 *** 78% 70 60 *** 58% 50 Responders % % 40 30 36% 20 21% 10 0 Placebo 4 mg BID 8 mg BID 12 mg BID *** P < 0.001 vs PBO 13
Slide 14: Common Treatment Emergent Adverse Events
Common (≥ 10%) Treatment Emergent Adverse Events (# Patients) CTP-543 CTP-543 CTP-543 Preferred Term Placebo 4 mg 8 mg 12 mg Headache 4 (9.1%) 5 (17.2%) 10 (26.3%) 7 (19.4%) Nasopharyngitis 1 (2.3%) 3 (10.3%) 3 (7.9%) 9 (25.0%) URI 7 (15.9%) 2 (6.9%) 2 (5.3%) 7 (19.4%) Acne 2 (4.5%) 4 (13.8%) 4 (10.
Slide 15: CTP-543 Response Over Treatment Period
CTP-543 Response Over Treatment Period: 12 mg BID Baseline Week 12 Week 24 15
Slide 16: CTP-543 Response Over Treatment Period
CTP-543 Response Over Treatment Period: 12 mg BID Baseline Week 12 Week 24 16
Slide 17: CTP-543 Response Over Treatment Period
CTP-543 Response Over Treatment Period: 8 mg BID Baseline Week 12 Week 24 17
Slide 18: CTP-543 Eyebrow/Eyelash Response Over Treatment Period
CTP-543 Eyebrow/Eyelash Response Over Treatment Period: 12 mg BID Baseline Week 24 18
Slide 19: Conclusion
Conclusion • The primary efficacy endpoint was met for 8 mg BID and 12 mg BID ‒ 58% of patients treated with 12 mg BID and 47% of patients treated with 8 mg BID of CTP-543 achieved a ≥50% reduction in their overall SALT score compared to 9% placebo (p’s <0.001) • Dose-related improvements for 8 mg B
Slide 20: September is Alopecia Areata Awareness Month
September is Alopecia Areata Awareness Month NASDAQ: CNCE www.concertpharma.com @ConcertPharma For additional information contact: Justine Koenigsberg ir@concertpharma.com
Concert Pharmaceuticals — Technical Presentation (September 2019) on 6ix